updated 7/31/2007 9:06:55 AM ET 2007-07-31T13:06:55

Johnson & Johnson said Tuesday it would reduce its global work force by up to 4 percent in a restructuring to cut costs as a number of its patents expire over the next few years.

The health care company, which says it employs about 121,000 people worldwide, predicted the restructuring would entail pretax charges totaling $550 million to $750 million in the second half of 2007.

Excluding the charges, Johnson & Johnson still expects to meet its 2007 profit targets.

Johnson & Johnson said the restructuring targets primarily its pharmaceuticals segments, which faces significant patent expirations over the next few years, and its Cordis stent-making unit.

Under the restructuring, Johnson & Johnson will consolidate certain operations at the pharmaceuticals segment and better integrate its Cordis business.

The company said the moves are expected to generate pretax, annual cost savings of $1.3 billion to $1.6 billion next year.

Johnson & Johnson said it will continue to invest in promising technologies and product opportunities in the fastest growing segments of the health care industry. The company still sees a full-year profit of $4.02 to $4.07 per share, versus the average analyst estimate of $4.06 per share, based on a survey by Thomson Financial.

Earlier this month, Johnson & Johnson, which employs about 121,000 people worldwide, said its second-quarter profit rose 9 percent, but U.S. sales of its Cypher drug-coated stents declined 41 percent. A drug-coated stent is a tiny mesh scaffold that props heart arteries and slowly releases a drug to keep them from clogging.

Sales of key anemia drug Procrit, formerly the company’s best-selling drug, slid 6 percent to $758 million during the quarter.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com